Roche Symposia at APVRS 2024

Join the Roche DME and nAMD Symposia where international experts will share the latest faricimab clinical and real-world data in an all-new, fun and interactive experience.

Changing the DME Game Plan With Faricimab

Dual Pathway, Drying and Durability

Friday 22 November 2024

12:45–13:45 SGT

Hall 406D

Chair

Gemmy Cheung
Singapore

Yi-Ting Hsieh
Taiwan

David Wong
Canada

Paul Mitchell
Australia

Changing the nAMD Game Plan With Faricimab

Dual Pathway, Drying and Durability

Saturday 23 November 2024

13:00–14:00 SGT

Hall 406D

Chair

Adrian Koh
Singapore

Jae Hui Kim
Korea

Timothy Lai
Hong Kong

Keiko Kataoka
Japan

Roche-Associated Scientific Sessions

DME/DR

nAMD/PCV

RVO

UME

Podium Presentations

Friday 22 November 2024

Session: Rapid Fire 2 – Intraocular Inflammation, Uveitis & Scleritis Venue: Room 334/335
11:12–11:18	Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study	Rupesh Agrawal, Singapore
11:24–11:30	IL-6 Inhibition with Vamikibart in Patients With Uveitic Macular Edema: Phase 3 MEERKAT and SANDCAT Trials	Yih-Shiou Hwang, Taiwan

Session: Rapid Fire 2 – Intraocular Inflammation, Uveitis & Scleritis
Venue: Room 334/335

11:12–11:18

Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study

Rupesh Agrawal, Singapore

11:24–11:30

IL-6 Inhibition with Vamikibart in Patients With Uveitic Macular Edema: Phase 3 MEERKAT and SANDCAT Trials

Yih-Shiou Hwang, Taiwan

Session: Rapid Fire 3 – Retina (Medical) Venue: Summit 2
11:30–11:35	Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)	Adrian Koh, Singapore
11:35–11:40	Efficacy, Durability and Safety of Faricimab in DME: 2-Year Results From China Subpopulation of Phase 3 RHINE Trial	Xiaodong Sun, China
11:45–11:50	Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Retinopathy (DR) Without Centre-Involved Diabetic Macular Edema (CI-DME): 2-Year Data From the Phase 3 Pavilion Trial	Timothy Lai, Hong Kong
12:15–12:20	Faricimab in Diabetic Macular Edema: Results From the RHONE-X Long-Term Extension Trial	Andrew Chang, Australia

Session: Rapid Fire 3 – Retina (Medical)
Venue: Summit 2

11:30–11:35

Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)

Adrian Koh, Singapore

11:35–11:40

Efficacy, Durability and Safety of Faricimab in DME: 2-Year Results From China Subpopulation of Phase 3 RHINE Trial

Xiaodong Sun, China

11:45–11:50

Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Retinopathy (DR) Without Centre-Involved Diabetic Macular Edema (CI-DME): 2-Year Data From the Phase 3 Pavilion Trial

Timothy Lai, Hong Kong

12:15–12:20

Faricimab in Diabetic Macular Edema: Results From the RHONE-X Long-Term Extension Trial

Andrew Chang, Australia

Sunday 24 November 2024

Session: Rapid Fire 5 – Retina (Medical) Venue: Room 331/332
11:30–11:35	Response of Large or Serous Pigment Epithelial Detachment to Faricimab Versus Aflibercept in Patients With Neovascular Age-Related Macular Degeneration: A Subgroup Analysis From TENAYA and LUCERNE	Yi-Ting Hsieh, Taiwan
11:15–11:20	Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies	Simon Szeto, Hong Kong
11:35–11:40	Faricimab for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial	Gemmy Cheung, Singapore
11:40–11:45	Global Clinical and Anatomical Outcomes With Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-country Prospective Non-interventional Study: The VOYAGER Study	Adrian Koh, Singapore
12:10–12:15	Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From the FARETINA-nAMD and FARWIDE-nAMD Studies	Tai-Chi Lin, Taiwan

Session: Rapid Fire 5 – Retina (Medical)
Venue: Room 331/332

11:30–11:35

Response of Large or Serous Pigment Epithelial Detachment to Faricimab Versus Aflibercept in Patients With Neovascular Age-Related Macular Degeneration: A Subgroup Analysis From TENAYA and LUCERNE

Yi-Ting Hsieh, Taiwan

11:15–11:20

Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From FARETINA-DME and FARWIDE-DME Studies

Simon Szeto, Hong Kong

11:35–11:40

Faricimab for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial

Gemmy Cheung, Singapore

11:40–11:45

Global Clinical and Anatomical Outcomes With Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-country Prospective Non-interventional Study: The VOYAGER Study

Adrian Koh, Singapore

12:10–12:15

Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From the FARETINA-nAMD and FARWIDE-nAMD Studies

Tai-Chi Lin, Taiwan

E-posters

Visual Acuity and Anatomic Improvements at Week 24 Maintained Through Week 72 With Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion in the Phase 3 BALATON and COMINO Studies: Results and Patient Case Profiles

Timothy Lai, Hong Kong

Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion: 24-Week Results From China Subpopulation of the Phase 3 BALATON Trial

Dawei Sun, China